How did PLSE's expenses trend impact Q4 2024 revenue?

Pulse Biosciences Inc. (PLSE) experienced a significant increase in Research and Development (R&D) expenses, reaching $10.66 million, and a rise in Selling, General, and Administrative (SG&A) expenses, reaching $9.6 million, in Q4 2024. However, the company's revenue for the quarter was not disclosed. The substantial investment in R&D and SG&A suggests that PLSE was likely focused on advancing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology and potentially preparing for market expansion or regulatory approvals. The high expenses could impact short-term profitability but are crucial for long-term growth and competitiveness in the bioelectric medicine sector.